Literature DB >> 22271902

Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival.

Csaba Bödör1, Aline Renneville, Matthew Smith, Aurélie Charazac, Sameena Iqbal, Pascaline Etancelin, Jamie Cavenagh, Michael J Barnett, Karolina Kramarzová, Biju Krishnan, András Matolcsy, Claude Preudhomme, Jude Fitzgibbon, Carolyn Owen.   

Abstract

While most myelodysplastic syndrome/acute myeloid leukemia cases are sporadic, rare familial cases occur and provide some insight into leukemogenesis. The most clearly defined familial cases result from inherited mutations in RUNX1 or CEBPA. Recently, novel germline mutations in GATA2 have been reported. We, therefore, investigated individuals from families with one or more first-degree relatives with myelodysplastic syndrome/acute myeloid leukemia with wild-type RUNX1 and CEBPA, for GATA2 mutations. Screening for other recurrent mutations was also performed. A GATA2 p.Thr354Met mutation was observed in a pedigree in which 2 first-degree cousins developed high-risk myelodys-plastic syndrome with monosomy 7. They were also observed to have acquired identical somatic ASXL1 mutations and both died despite stem cell transplantation. These findings confirm that germline GATA2 mutations predispose to familial myelodysplastic syndrome/acute myeloid leukemia, and that monosomy 7 and ASXL1 mutations may be recurrent secondary genetic abnormalities triggering overt malignancy in these families.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22271902      PMCID: PMC3366655          DOI: 10.3324/haematol.2011.054361

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  20 in total

1.  Familial childhood monosomy 7 and associated myelodysplasia.

Authors:  Sujata Gaitonde; Redouane Boumendjel; Ronald Angeles; Damiano Rondelli
Journal:  J Pediatr Hematol Oncol       Date:  2010-08       Impact factor: 1.289

2.  Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

Authors:  Felicitas Thol; Inna Friesen; Frederik Damm; Haiyang Yun; Eva M Weissinger; Jürgen Krauter; Katharina Wagner; Anuhar Chaturvedi; Amit Sharma; Martin Wichmann; Gudrun Göhring; Christiane Schumann; Gesine Bug; Oliver Ottmann; Wolf-Karsten Hofmann; Brigitte Schlegelberger; Michael Heuser; Arnold Ganser
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

3.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; Julien Roquain; José Adélaïde; Nadine Carbuccia; Benjamin Esterni; Pascal Finetti; Anne Murati; Christine Arnoulet; Hacène Zerazhi; Hacène Fezoui; Zoulika Tadrist; Meyer Nezri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2010-09-29       Impact factor: 6.998

5.  Mutation of CEBPA in familial acute myeloid leukemia.

Authors:  Matthew L Smith; Jamie D Cavenagh; T Andrew Lister; Jude Fitzgibbon
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

6.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies.

Authors:  Andrew J Dunbar; Lukasz P Gondek; Christine L O'Keefe; Hideki Makishima; Manjot S Rataul; Hadrian Szpurka; Mikkael A Sekeres; Xiao Fei Wang; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

8.  Mutation in TET2 in myeloid cancers.

Authors:  François Delhommeau; Sabrina Dupont; Véronique Della Valle; Chloé James; Severine Trannoy; Aline Massé; Olivier Kosmider; Jean-Pierre Le Couedic; Fabienne Robert; Antonio Alberdi; Yann Lécluse; Isabelle Plo; François J Dreyfus; Christophe Marzac; Nicole Casadevall; Catherine Lacombe; Serge P Romana; Philippe Dessen; Jean Soulier; Franck Viguié; Michaela Fontenay; William Vainchenker; Olivier A Bernard
Journal:  N Engl J Med       Date:  2009-05-28       Impact factor: 91.245

9.  Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia.

Authors:  Donald C Vinh; Smita Y Patel; Gulbu Uzel; Victoria L Anderson; Alexandra F Freeman; Kenneth N Olivier; Christine Spalding; Stephen Hughes; Stefania Pittaluga; Mark Raffeld; Lynn R Sorbara; Houda Z Elloumi; Douglas B Kuhns; Maria L Turner; Edward W Cowen; Danielle Fink; Debra Long-Priel; Amy P Hsu; Li Ding; Michelle L Paulson; Adeline R Whitney; Elizabeth P Sampaio; David M Frucht; Frank R DeLeo; Steven M Holland
Journal:  Blood       Date:  2009-12-29       Impact factor: 22.113

10.  Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.

Authors:  Carolyn J Owen; Cynthia L Toze; Anna Koochin; Donna L Forrest; Clayton A Smith; Jane M Stevens; Shannon C Jackson; Man-Chiu Poon; Gary D Sinclair; Brian Leber; Peter R E Johnson; Anthony Macheta; John A L Yin; Michael J Barnett; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2008-08-21       Impact factor: 22.113

View more
  45 in total

Review 1.  GATA2 deficiency.

Authors:  Amy P Hsu; Lisa J McReynolds; Steven M Holland
Journal:  Curr Opin Allergy Clin Immunol       Date:  2015-02

2.  MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations.

Authors:  Lisa J McReynolds; Yanqin Yang; Hong Yuen Wong; Jingrong Tang; Yubo Zhang; Matthew P Mulé; Janine Daub; Cindy Palmer; Ladan Foruraghi; Qingguo Liu; Jun Zhu; Weixin Wang; Robert R West; Marielle E Yohe; Amy P Hsu; Dennis D Hickstein; Danielle M Townsley; Steven M Holland; Katherine R Calvo; Christopher S Hourigan
Journal:  Leuk Res       Date:  2018-12-04       Impact factor: 3.156

3.  GATA2 and secondary mutations in familial myelodysplastic syndromes and pediatric myeloid malignancies.

Authors:  Xinan Wang; Hideki Muramatsu; Yusuke Okuno; Hirotoshi Sakaguchi; Kenichi Yoshida; Nozomu Kawashima; Yinyan Xu; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Shoji Saito; Yozo Nakazawa; Taro Masunari; Tadashi Hirose; Shaimaa Elmahdi; Atsushi Narita; Sayoko Doisaki; Olfat Ismael; Hideki Makishima; Asahito Hama; Satoru Miyano; Yoshiyuki Takahashi; Seishi Ogawa; Seiji Kojima
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

4.  Characterisation of a compound in-cis GATA2 germline mutation in a pedigree presenting with myelodysplastic syndrome/acute myeloid leukemia with concurrent thrombocytopenia.

Authors:  C N Hahn; P J Brautigan; C-E Chong; A Janssan; P Venugopal; Y Lee; A E Tims; M S Horwitz; M Klingler-Hoffmann; H S Scott
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

Review 5.  Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms.

Authors:  Emery H Bresnick; Kirby D Johnson
Journal:  Blood Adv       Date:  2019-07-09

6.  Collaborating constitutive and somatic genetic events in myeloid malignancies: ASXL1 mutations in patients with germline GATA2 mutations.

Authors:  Jean-Baptiste Micol; Omar Abdel-Wahab
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

Review 7.  Familial leukemias.

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2015-02

8.  High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia.

Authors:  Marlène Pasquet; Christine Bellanné-Chantelot; Suzanne Tavitian; Naïs Prade; Blandine Beaupain; Olivier Larochelle; Arnaud Petit; Pierre Rohrlich; Christophe Ferrand; Eric Van Den Neste; Hélène A Poirel; Thierry Lamy; Marie Ouachée-Chardin; Véronique Mansat-De Mas; Jill Corre; Christian Récher; Geneviève Plat; Françoise Bachelerie; Jean Donadieu; Eric Delabesse
Journal:  Blood       Date:  2012-12-06       Impact factor: 22.113

Review 9.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

Review 10.  Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.

Authors:  Allison H West; Lucy A Godley; Jane E Churpek
Journal:  Ann N Y Acad Sci       Date:  2014-01-27       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.